TrialEuropean journal of cancer (Oxford, England : 1990)2022

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.

Andrea B Apolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.